The Infectious Bursal Disease Vaccine, Live (Strain B87) Veterinary Grade API is a live attenuated infectious bursal disease virus antigen intermediate derived from the B87 master seed lot and intended solely for further manufacture into finished veterinary vaccines for chickens. The product identifier commonly combines the strain designation, lyophilisation matrix code, and target infectivity titre, for example IBDV-B87-LYO-10^5.0 TCID50. It is available for further processing into powders, granules, premixes, oral solutions, and sterile injectable presentations; tablet and capsule formats require separate validation because compaction shear and low water activity can reduce live-virus infectivity. The API is not a ready-to-administer vaccine, and the B87 strain is used for active immunisation of chickens against infectious bursal disease. The B87 strain is distinguished from mild and standard intermediate live IBDV strains by its attenuation phenotype, bursal replication characteristics, and behaviour in the presence of maternally derived antibody.

What Constitutes the B87 API in Finished Veterinary Dosage Forms?

The API is classified under the general monograph for live avian infectious bursal disease vaccine, Ph. Eur. 0587. The live virus is produced in specific-pathogen-free embryonated chicken eggs or chicken embryo fibroblast cultures and is harvested as a clarified, stabilised bulk fluid before lyophilisation. The active moiety is replication-competent attenuated IBDV; the VP2 capsid protein is the primary neutralising antigen, and identity is confirmed by reverse transcription polymerase chain reaction targeting the VP2 hypervariable region or by a monoclonal antibody panel. Finished dosage forms prepared from the API include oral powder and granule blends containing carbohydrate or protein stabilisers such as sucrose, dextran, skimmed milk, and hydrolysed gelatin; aqueous solutions for drinking-water or eyedrop use; and sterile injectable solutions for in ovo or subcutaneous administration where the marketing authorisation permits. Because the API is a biological product, batch-to-batch infectivity titre variance is controlled through validated seed lot production, harvest pooling, and lyophilisation cycle parameters. The receiving manufacturer must establish a minimum release titre that correlates with efficacy in the target chicken population; Ph. Eur. 0587 does not prescribe a universal numeric titre for all strains, but live IBDV vaccines typically require not less than 10^3.0 TCID50 per immunising dose, with higher titres often specified for intermediate-plus strains such as B87. Published data for B87-specific bulk titres in the open literature is limited.

Release Specifications, Infectivity Titration, and Residual Moisture Boundaries

Residual moisture is a critical control point because water content above the collapse limit accelerates viral inactivation during storage, while overdried cakes below 0.5% water can lose capsid hydration and reconstitute poorly. Karl Fischer titration per Ph. Eur. 2.2.32 is used with a release acceptance range of 0.5–3.0% for lyophilised B87 intermediates. Infectivity titration is performed by endpoint dilution in chicken embryo fibroblasts or specific-pathogen-free embryonated chicken eggs, and the TCID50 or EID50 value is calculated using the Reed-Muench or Spearman-Kärber method. Replicate titration variance for live IBDV APIs is generally within ±0.3 log10; batches below the minimum release titre are rejected unless the registered production protocol permits blending with a higher-titre harvest. Lyophilisation cycle design must maintain product temperature below the collapse temperature of the stabiliser matrix. A typical cycle for sucrose-based live viral APIs uses a primary drying shelf temperature of −25 °C to −35 °C at chamber pressure 50–100 µbar for 24–48 h, followed by a secondary drying ramp to 20–25 °C; the B87-specific cycle must be validated because excipient ratios and fill depth influence drying kinetics. For injectable solutions, pre-filtration bioburden should be below 10 CFU/100 mL, and the final filtered solution must meet the sterility and endotoxin limits shown in the release specification table.

On a production line, the B87 lyophilised cake is first milled with a cryogenic jet mill using chilled nitrogen below −50 °C, then blended with prechilled stabilisers in a low-shear ribbon blender or bin blender at room temperature not exceeding 25 °C and relative humidity below 30% RH. The blend is filled into foil-laminated sachets for oral powders or granules; moisture-barrier packaging with a desiccant pouch is used because the stabiliser matrix is hygroscopic. Wet granulation is generally unsuitable for live viral APIs because the water addition and drying step can reduce infectivity titre by more than 1 log10 TCID50; if a granulated premix is required, fluidised-bed top-spray granulation is used with inlet air temperature maintained below 30 °C and outlet air humidity below 20% RH. Tablet compression of live viral APIs is not generally recommended; if required, direct-compression formulations are processed at pressures below 25 MPa, with tooling prechilled to 4–8 °C and external lubrication using sodium stearyl fumarate rather than magnesium stearate. Capsule filling uses tamping force minimisation and hard gelatin shells conditioned to <12% moisture; published data for B87-specific infectivity retention in compressed oral solids is limited. Injectable solutions are prepared by dissolving the API in phosphate-buffered saline or Hanks’ balanced salt solution containing 2–5% w/v hydrolysed gelatin or sucrose, aseptically filtered, and filled under isolator conditions. The finished injection is adjusted to osmolality 280–320 mOsm/kg and pH 6.5–7.5 to preserve VP2 capsid integrity.

When Strain B87 Replaces a Mild or Standard Intermediate Live IBDV Seed in a Manufacturing Line

B87 is classified as an intermediate-plus live IBDV strain, whereas many legacy live IBDV seeds are classified as mild or standard intermediate. The B87 VP2 hypervariable region segregates with intermediate-plus reference viruses, and the strain exhibits stronger bursal replication than mild strains under moderate maternal antibody titres. In manufacturing, this difference can increase harvest infectivity titres, but it also raises the required stabiliser concentration and narrows the safe lyophilisation window because higher viral load increases the demand for amorphous matrix protectants. Compared with hot IBDV strains, B87 has lower bursal lesion potential and is intended for vaccination of broilers and layers from 7 to 14 days of age when field challenge is moderate. Unlike immune-complex live IBDV vaccines, the B87 API is not coated with hyperimmune serum and must be treated as a replication-competent virus in downstream processing. Unlike inactivated whole-virus IBDV APIs, the B87 live API requires cold-chain handling and cannot be formulated into oil emulsion without destroying infectivity. These differences must be reflected in facility segregation and cleaning validation; IBDV is non-enveloped and is not inactivated by all common disinfectants, so validated virucidal agents such as iodophors or aldehydes must be used in equipment changeover procedures.

Thermal Stability and Excipient Compatibility Data for Freeze-Dried B87 Intermediates

The thermal stability of the B87 API depends on the lyoprotectant matrix and residual moisture. Differential scanning calorimetry of lyophilised viral cakes typically shows a glass transition temperature between 40 °C and 65 °C when sucrose or trehalose is the primary stabiliser; storage below 2–8 °C maintains a large margin below the glass transition, while excursions above 25 °C can cause cake collapse and titre loss. Excipient compatibility testing should include binary mixtures of the API with lactose, mannitol, sucrose, dextran, skimmed milk, gelatin, and phosphate buffers; mannitol can crystallise during lyophilisation and is therefore used with caution because crystalline mannitol can reduce the amorphous stabiliser fraction available to the virus. Polyvinylpyrrolidone is sometimes used as a binder in granulated premixes, but its hygroscopicity requires moisture-barrier packaging. Accelerated screening at 37 °C for 7 days is often used to compare candidate stabiliser systems; a titre loss below 0.5 log10 under these conditions suggests an acceptable matrix, but the B87-specific acceptance limit must be validated by the receiving manufacturer. The API is incompatible with strong oxidising agents, aldehydes, and quaternary ammonium disinfectants, which rapidly inactivate non-enveloped IBDV particles; direct contact with chlorine-based cleaning residues in equipment must be avoided. Published data for B87-specific thermal degradation kinetics in tablet matrices is limited; therefore, any compressed oral dosage form must be supported by viral titre stability studies under 25 °C at 60% RH and 40 °C at 75% RH according to the stability protocol of the receiving manufacturer.

Differences from inactivated whole-virus IBDV APIs are substantial. The B87 API retains infectivity and requires cold-chain handling and lyophilisation, whereas an inactivated IBDV antigen can be incorporated into water-in-oil emulsions and is not sensitive to ambient temperature in the same way. The live B87 virus replicates in the bursa of Fabricius and stimulates mucosal immunity after drinking-water or eyedrop administration; inactivated antigen requires injection and primarily induces circulating antibody. Compared with recombinant vectored IBDV products, the B87 API is a complete live attenuated virus and therefore demands stricter containment and extraneous agent screening, but it does not depend on a heterologous vector backbone. Compared with immune-complex live IBDV vaccines, the B87 API is unbound to hyperimmune serum and has a different maternal antibody break-through pattern, which affects the age of administration and the required dose. Analytical differentiation of B87 from other strains uses VP2 sequencing, restriction fragment length polymorphism, or strain-specific real-time RT-PCR; master seed sequencing should be included in the API dossier to prevent seed misidentification. These differences must be reflected in the facility segregation, cleaning validation, and personnel protection procedures used by downstream manufacturers; live IBDV is non-enveloped and resistant to some disinfectants, so validated virucidal agents such as iodophors or aldehydes must be used in line with 9 CFR 113.37 supporting methods.

In broiler and layer vaccination programmes, the B87 API is most frequently processed into freeze-dried cakes for reconstitution in drinking water or eyedrop diluent, and into granulated premixes for mass administration via water proportioners or feed systems. The finished vaccine is generally administered to chickens from 7 to 14 days of age as a single dose, with revaccination after 7 to 10 days if maternal antibody interference is documented; because B87 is an intermediate-plus strain, the exact age and dose must be judged by serological monitoring. The API is not intended for direct use in birds and is not an inactivated antigen; accidental injection of undiluted API into birds or humans is a biological hazard and should be managed under veterinary pharmacovigilance procedures. Distribution of the API in powder or granule form requires cold-chain logistics at 2–8 °C, whereas frozen liquid presentations are stored at −20 °C or below with controlled thawing before formulation. Each receiving manufacturer must re-qualify the API against its own seed lot correlation, because infectivity titre and immunogenicity can shift when the product is transferred from one stabiliser system to another. The B87 API is differentiated from inactivated IBDV APIs by its ability to replicate in the bursa of Fabricius and from immune-complex products by the absence of bound hyperimmune serum; these differences create distinct storage, handling, and safety profiles in downstream finished-product manufacturing.